Clinical Trial Update: A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates JNJ-79635322 in combination with daratumumab, with or without lenalidomide, or in combination with pomalidomide, for multiple myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (Darzalex) (daratumumab)
• JNJ-79635322
• Lenalidomide (Revlimid) (lenalidomide)
• Pomalidomide (Pomalyst) (pomalidomide)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING